Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02045862 · ClinicalTrials.gov registry record · Phase 3
A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder
A Phase 3 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,829
- Enrollment target
NCT02045862 is a Phase 3 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 1,829 participants.
The verdict
NCT02045862, a Phase 3 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,829 participants
- Enrollment target
Study Summary
The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.
Interventions
- DRUG Mirabegron
- DRUG Solifenacin succinate
- DRUG Placebo to match solifenacin
- DRUG Placebo to match mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,829 participants |
| Start Date | 2014-03-17 |
| Est. Completion | 2016-09-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02045862
The ClinicalTrials.gov registry entry for NCT02045862 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,829 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Mirabegron is the first listed.
NCT02045862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02045862 about?
NCT02045862 is a clinical study titled "A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder". The purpose of this study was to examine how well the combination of two medicines (solifenacin succinate and mirabegron) worked compared to each medicine alone in the treatment of bladder problems, and how safe they were for long term use.
What is the current status of trial NCT02045862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,829 participants. The study started on 2014-03-17. Estimated completion is 2016-09-08.
What interventions are being tested in trial NCT02045862?
The interventions under investigation include: Mirabegron (DRUG), Solifenacin succinate (DRUG), Placebo to match solifenacin (DRUG), Placebo to match mirabegron (DRUG).
Who is sponsoring clinical trial NCT02045862?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.